Acute attacks of hereditary angioedema (HAE)

Active Ingredient: Sebetralstat

Indication for Sebetralstat

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Sebetralstat is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.

For this indication, competent medicine agencies globally authorize below treatments:

300 mg once

For:

Dosage regimens

Regimen A

Oral, 300 milligrams sebetralstat, one dose.

Regimen B

Oral, 300 milligrams sebetralstat, one dose, over the duration of 3 hours. Afterwards, in case that there is poor response to treatment, oral, 300 milligrams sebetralstat, one dose.

Detailed description

The recommended dose is 300 mg administered at the earliest recognition of an attack. A second dose may be taken 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur. No more than two doses should be administered in a 24 hour period.

Patients with normal C1-INH HAE (nC1 INH)

Consideration should be given to discontinuing treatment in patients with normal C1-INH HAE (nC1-INH) if a clinical response is not observed.

Elderly

No dose adjustment is required for patients above 65 years of age.

Patients taking CYP3A4 inducers

No dose adjustment is required when taking weak CYP3A4 inducers.

In patients taking moderate or strong CYP3A4 inducers a single dose of 900 mg is recommended when treating an HAE attack.

Active ingredient

Sebetralstat

Sebetralstat is a competitive, reversible inhibitor of plasma kallikrein (PKa). By inhibiting PKa, sebetralstat blocks the cleavage of high molecular weight kininogen (HK) and the subsequent generation of bradykinin (BK), thereby halting HAE attack progression which is associated with increased vascular permeability and oedema formation. Sebetralstat also suppresses the activation of positive feedback mechanism of the kallikrein-kinin system (KKS), thereby reducing factor XIIa (FXIIa) and additional PKa production.

Read more about Sebetralstat

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.